Pharsight

Savaysa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7365205 DAIICHI SANKYO INC Diamine derivatives
Apr, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition
Mar, 2028

(3 years from now)

Savaysa is owned by Daiichi Sankyo Inc.

Savaysa contains Edoxaban Tosylate.

Savaysa has a total of 2 drug patents out of which 0 drug patents have expired.

Savaysa was authorised for market use on 08 January, 2015.

Savaysa is available in tablet;oral dosage forms.

Drug patent challenges can be filed against Savaysa from 08 January, 2019.

The generics of Savaysa are possible to be released after 28 March, 2028.

Drug Exclusivity Drug Exclusivity Expiration
M(M-14) Oct 18, 2026
M(M-243) Aug 09, 2022
New Chemical Entity Exclusivity(NCE) Jan 08, 2020

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using EDOXABAN TOSYLATE ingredient

NCE-1 date: 08 January, 2019

Market Authorisation Date: 08 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SAVAYSA before it's drug patent expiration?
More Information on Dosage

SAVAYSA family patents

Family Patents